Revealing the hidden biological mechanisms of disease to discover the next generation of breakthrough drugs

What if we could learn the hidden circuitry of human disease directly from patient tissue instead of cell lines or animal models or relying on fragmented and incomplete scientific literature?

What if we could go beyond discovering often spurious patterns and correlations from high-dimensional multi-omic data and instead directly learn the biological mechanisms driving disease outcomes “hidden” in the data?

What if we could simulate the efficacy and safety of a drug at the individual patient level before running clinical trials to better select the right patients?

At Aitia (pronounced “Ay-tee-ah”), derived from the Greek word for causality, we are rapidly turning this aspiration into reality through the convergence of multi-omic patient data, high-performance computing, and causal learning and AI. Our mission at Aitia is to discover the next generation of breakthrough drugs to improve outcomes for patients by creating Digital Twins of human disease from multi-omic patient data and causal AI. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development across oncology, neurodegeneration, and immunology.

Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease

Becoming Aitia: why GNS shifted from AI provider to drug discoverer

GNS Rebrands as Aitia to Focus on AI-Enabled Drug Discovery

Aitia and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development

Colin Hill Opening Keynote at the Annual Merck Technology Symposium 2022

ASH Poster | Causal AI in silico Patient Model Identifies Minichromosome Maintenance (MCM) Family Genes as Novel Predictors of Overall Survival in Multiple Myeloma

CTAD Poster | Causal in silico patient models can inform Alzheimer’s disease patient identification and endpoint selection for early-stage clinical trials

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide